Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBIT: 2019-2024

Historic EBIT for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$23.2 million.

  • GeneDx Holdings' EBIT rose 58.21% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 117.28%. This contributed to the annual value of -$23.2 million for FY2024, which is 87.15% up from last year.
  • As of FY2024, GeneDx Holdings' EBIT stood at -$23.2 million, which was up 87.15% from -$180.6 million recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' EBIT registered a high of -$23.2 million during FY2024, and its lowest value of -$667.7 million during FY2022.
  • Over the past 3 years, GeneDx Holdings' median EBIT value was -$180.6 million (recorded in 2023), while the average stood at -$290.5 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 695.69% in 2020, then soared by 87.15% in 2024.
  • Over the past 5 years, GeneDx Holdings' EBIT (Yearly) stood at -$242.0 million in 2020, then tumbled by 84.36% to -$446.1 million in 2021, then crashed by 49.65% to -$667.7 million in 2022, then spiked by 72.95% to -$180.6 million in 2023, then soared by 87.15% to -$23.2 million in 2024.